Esbriet (pirfenidone) is employed to treat a respiratory organ sickness referred to as disorder respiratory organfibrosis(IPF). IPF causes connective tissue to make deep among your lungs. The connective tissue thickens and becomes stiff or thick over time, which might build it tougher for your lungs to figure. minimized respiratory organoperate will build it laborious for you to breathe. different medical issues will occur once your brain, heart, anddifferent organs don’t get enough atomic number 8.
The explanation for IPF is commonly unknown, however this condition could be a progressive sickness that may be fatal. Esbriet isn’t a cure for IPF, however this medication could slow the progress of this sickness.
Esbriet may additionally be used for functions unlisted during this medication guide.
Submit your review
Get emergency medical help if you have any of these signs of an allergic reaction to Esbriet: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using Esbriet and call your doctor at once if you have:
severe ongoing stomach pain, vomiting, diarrhea;
burning or pain in your esophagus or throat;
easy bruising or bleeding (nosebleeds, bleeding gums); or
liver problems--nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Common Esbriet side effects may include:
nausea, vomiting, loss of appetite;
stomach pain, heartburn, upset stomach;
headache, dizziness, tired feeling;
cold symptoms such as stuffy nose, sneezing, sore throat;
sleep problems (insomnia);
joint pain; or
abnormal liver function tests.
Usual Adult Dose for Idiopathic Pulmonary Fibrosis: Initial dose: -Days 1 to 7: 267 mg (one capsule) orally three times a day -Days 8 to 14: 534 mg (two capsules) orally three times a day Maintenance/Maximum dose (Day 15 onward): 801 mg (three capsules) orally three times a day Comments: -Take with food to reduce nausea and dizziness. -Doses should be taken at the same time each day. Use: Idiopathic pulmonary fibrosis (IPF)